FDG PET/CT as a tool to provide the prognostic stratification and response assessment of metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride (Ra-223)

被引：0
|
作者：
Bauckneht, M. [1 ]
Capitanio, S. [1 ]
Fornarini, G. [1 ]
Ceriani, V. [1 ]
Ippoliti, M. [1 ]
Ciarmiello, A. [2 ]
Giovacchini, G. [2 ]
Bongioanni, F. [3 ]
Piccardo, E. [3 ]
Agnese, G. [3 ]
Di Ciolo, L. [3 ]
Sambuceti, G. [1 ]
Morbelli, S. [1 ]
机构：
[1] IRCCS AUO San Martino IST, Genoa, Italy
[2] S Andrea Hosp, La Spezia, Italy
[3] S Corona Hosp, Pietra Ligure, SV, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2018年 / 45卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP-0577
引用
收藏
页码：S527 / S528
页数：2
相关论文
共 50 条
  • [1] Role of FDG PET/CT in the prognostic stratification and response assessment of castration-resistant prostate cancer treated with radium-223 dichloride
    Donegani, M.
    Capitanio, S.
    Vitti, M.
    Fornarini, G.
    Miceli, A.
    Zanardi, E.
    Mencoboni, M.
    Marini, C.
    Boccardo, F.
    Sambuceti, G.
    Morbelli, S.
    Bauckneht, M.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S627 - S628
  • [2] Fracture risk after radium-223 (Ra-223) in metastatic castration resistant prostate cancer (mCRPC).
    Alonzi, Roberto
    Parker, Chris C.
    Tunariu, Nina
    Koh, Dow-Mu
    Staffurth, John
    Blackledge, Matthew D.
    Padhani, Anwar R.
    Tree, Alison
    Stidwill, Helen
    Finch, Jessica
    Chatfield, Peter
    Perry, Sophie
    Tovey, Holly
    Hall, Emma
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Fracture risk in men with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra 223)
    Hijab, A.
    Tunariu, N.
    Tovey, H.
    Alonzi, R.
    Tree, A.
    Staffurth, J.
    Blackledge, M.
    Padhani, A. R.
    Stidwill, H.
    Finch, J.
    Chatfield, P.
    Perry, S.
    Koh, D-M.
    Hall, E.
    Parker, C.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S539 - S539
  • [4] A phase IIa study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)
    Petrylak, D. P.
    Vaishampayan, U. N.
    Patel, K. R.
    Higano, C. S.
    Albany, C.
    Dawson, N. A.
    Mehlhaff, B. A.
    Quinn, D. I.
    Nordquist, L. T.
    Wagner, V. J.
    Shen, J.
    Trandafir, L.
    Sartor, O.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 340 - 341
  • [5] Radium-223 (Ra-223) in asymptomatic metastatic castration-resistant prostate cancer (mCRPC) patients treated in an international early access program (iEAP).
    Heidenreich, Axel
    Gillessen, Silke
    Heinrich, Daniel
    Keizman, Daniel
    O'Sullivan, Joe M.
    Carles, Joan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [6] Pain evaluation in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO observation study
    Palmedo, H.
    Eschmann, S.
    Werner, A.
    Selinski, I.
    Moellers, M-O.
    Kalinovsky, J.
    Benson, A.
    Poeppel, T.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 336 - 336
  • [7] A randomized phase 2 study investigating 3 dosing regimens of radium-223 dichloride (Ra-223) in bone metastatic castration-resistant prostate cancer (mCRPC).
    Sternberg, Cora N.
    Saad, Fred
    Graff, Julie Nicole
    Peer, Avivit
    Vaishampayan, Ulka N.
    Leung, Eugene
    Rosenbaum, Eli
    Gurney, Howard
    Epstein, Richard
    Davis, Ian D.
    Wu, Bingyan
    Trandafir, Lucia
    Wagner, Volker Jean
    Hussain, Maha
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Efficacy of radium-223 dichloride in castration-resistant metastatic prostate cancer
    Sobrevilla Calvo, Pedro de Jesus
    [J]. GACETA MEXICANA DE ONCOLOGIA, 2016, 15 : 26 - 27
  • [9] Pain efficacy with radium-223 (Ra-223) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the PARABO observational study
    Palmedo, H.
    Ahmadzadehfar, H.
    Eschmann, S.
    Selkinski, I.
    Straube, F.
    Niesen, A.
    Schoenberger, J.
    Barsegian, V.
    Liepe, K.
    Mottaghy, F. M.
    Guan, R.
    Pinkert, J.
    Buetikofer, S.
    Herrmann, K.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S641 - S641
  • [10] Single-Institution Experience With Radium-223 Dichloride (Ra-223) for Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
    Cox, B. W.
    Wang, L.
    Bradley, T.
    Gu, B.
    Kelley, K.
    Potters, L.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S470 - S470
12345